Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10

Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) derived from HAdV with naturally low rates of pre-existing immunity will be beneficial for future clinical translation. We generated a low-seroprevalence HAdV-D10 serotype vector incorporating an αvβ6...

Descripción completa

Detalles Bibliográficos
Autores principales: Bates, Emily A., Davies, James A., Váňová, Jana, Nestić, Davor, Meniel, Valerie S., Koushyar, Sarah, Cunliffe, Tabitha G., Mundy, Rosie M., Moses, Elise, Uusi-Kerttula, Hanni K., Baker, Alexander T., Cole, David K., Majhen, Dragomira, Rizkallah, Pierre J., Phesse, Toby, Chester, John D., Parker, Alan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971729/
https://www.ncbi.nlm.nih.gov/pubmed/35399606
http://dx.doi.org/10.1016/j.omto.2022.03.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971729/
https://www.ncbi.nlm.nih.gov/pubmed/35399606
http://dx.doi.org/10.1016/j.omto.2022.03.007

Ejemplares similares